The World Health Organization (WHO) has escalated the health risk classification for the ongoing Ebola outbreak in the Democratic Republic of Congo to ‘very high’. This decision comes in light of alarming statistics revealing nearly 750 suspected cases and 177 reported deaths linked to this outbreak, which has been attributed to the Bundibugyo strain of the virus. While the situation remains classified as ‘low’ on a global scale, the implications for local and regional health systems are significant and concerning.
Rising Cases and Fatalities
As of the latest reports, the Democratic Republic of Congo (DRC) has confirmed 82 cases of Ebola, with seven fatalities. The WHO’s Director-General, Dr Tedros Adhanom Ghebreyesus, indicated that the regional risk in Africa is regarded as ‘high’, further underscoring the urgency of the situation. The Bundibugyo strain, though less common than other variants, is still highly lethal, with approximately one-third of infected individuals succumbing to the illness.
The WHO’s announcement was made during a news briefing in Geneva, where Dr Tedros emphasised the importance of addressing the outbreak with heightened vigilance. He noted two confirmed cases of Bundibugyo in Uganda, linked to individuals who had travelled from the DRC. The stability of the situation in Uganda, despite these cases, offers a glimmer of hope, yet the response in the DRC is hampered by violence and insecurity.
Vaccine Development Efforts
In a positive development, scientists at Oxford University are working on a new vaccine that could enter clinical trials within the next two to three months. This vaccine, based on the same innovative technology used for the AstraZeneca COVID-19 vaccine, remains unproven, necessitating thorough animal and human testing. The Serum Institute of India is poised to manufacture the vaccine en masse once Oxford provides the necessary medical-grade materials.
In addition to this initiative, another experimental Bundibugyo vaccine is in the pipeline, although it may take six to nine months before it reaches the testing phase. Dr Vasee Moorthy, WHO’s advisor on research and development, referred to this vaccine as “the most promising” in the current context, potentially offering a solution comparable to existing treatments for the more prevalent Zaire strain of Ebola.
Community Response and Challenges
The fear surrounding the Ebola outbreak has intensified in eastern DRC, where reports indicate that some communities are resorting to